Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Lv, Hongcheng ^a   Shi, Yang ^a   Zhang, Li ^a   Zhang, Dan ^a   Liu, Guang ^a   Yang, Zhengduo ^a   Li, Yan ^a   Fei, Fei ^a   Zhang, Shiwu ^a  

^a TIANJIN UNION MEDICAL CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; S PHASE KINASE ASSOCIATED PROTEIN 2; STATHMIN; CELL CYCLE PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GRADING; CELL BUDDING; CELL MIGRATION; CONTROLLED STUDY; CYSTADENOMA; DAUGHTER CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MIDDLE AGED; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; POLYPLOID GIANT CANCER CELL; PROTEIN EXPRESSION; STROMA; CANCER STAGING; GENE EXPRESSION REGULATION; GIANT CELL CARCINOMA; METABOLISM; OVARY TUMOR; PATHOLOGY; POLYPLOIDY; TUMOR CELL LINE;

CARCINOMA, GIANT CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN E; CYSTADENOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYPLOIDY; S-PHASE KINASE-ASSOCIATED PROTEINS; STATHMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84908114198     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-576     Document Type: Article

References (44)

1. Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman AK, Boruta DM, Schorge JO, del Carmen MG. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 2013, 131(1):46-51.
2. Yin M, Li C, Li X, Lou G, Miao B, Liu X, Meng F, Zhang H, Chen X, Sun M, Ling Q, Zhou R. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol 2011, 104(1):29-36.
3. Palmer J, Jivraj S, Galimberti A, Paterson M. Serous ovarian carcinoma in pregnancy. BMJ Case Rep 2009, 2009. bcr04.2009.1809.
4. Demsky R, McCuaig J, Maganti M, Murphy KJ, Rosen B, Armel SR. Keeping it simple: genetics referrals for all invasive serous ovarian cancers. Gynecol Oncol 2013, 130(2):329-333.
5. George SH, Shaw P. BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol 2014, 4:5.
6. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 2001, 11(5):403-408.
7. Davidson B, Smith Y, Nesland JM, Kaern J, Reich R, Trope CG. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. Hum Pathol 2013, 44(11):2449-2460.
8. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Canc Res: CR 2012, 31:14.
9. Zhang S, Mercado-Uribe I, Hanash S, Liu J. iTRAQ-based proteomic analysis of polyploid giant cancer cells and budding progeny cells reveals several distinct pathways for ovarian cancer development. PloS One 2013, 8(11):e80120.
10. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 2014, 33(1):116-128.
11. Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol 2011, 30(3):205-217.
12. Davidson B, Skrede M, Silins I, Shih Ie M, Trope CG, Florenes VA. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 2007, 110(6):1264-1271.
13. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007, 26(7):1003-1012.
14. Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Canc Therapeut 2006, 5(12):3248-3257.
15. Sadow PM, Rumilla KM, Erickson LA, Lloyd RV. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors. Endocr Pathol 2008, 19(2):97-103.
16. Wei SH, Lin F, Wang X, Gao P, Zhang HZ. Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma. Acta Histochem 2008, 110(1):59-65.
17. Fuster JJ, Gonzalez JM, Edo MD, Viana R, Boya P, Cervera J, Verges M, Rivera J, Andres V. Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J 2010, 24(8):2998-3009.
18. Deubzer HE, Ehemann V, Kulozik AE, Westermann F, Savelyeva L, Kopp-Schneider A, Riester D, Schwab M, Witt O. Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett 2008, 264(1):21-28.
19. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D, Scrima M, Montero-Conde C, Cito L, Monaco M, Motti ML, Pasquinelli R, Agosti V, Robledo M, Fusco A, Viglietto G. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr Relat Cancer 2007, 14(2):405-420.
20. Hung WC, Tseng WL, Shiea J, Chang HC. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 2010, 288(2):156-161.
21. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004, 28(4):496-504.
22. Zhang S, Mercado-Uribe I, Liu J. Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int J Cancer 2014, 134(3):508-518.
23. Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 2008, 39(3):444-451.
24. Zhang S, Mercado-Uribe I, Liu J. Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Lett 2013, 333(2):205-212.
25. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996, 271(5248):499-502.
26. Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, Jimenez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzman M, Gili M, Rodriguez O, Rodriguez S, Perez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011, 108(9):3761-3766.
27. Xiangming C, Natsugoe S, Takao S, Hokita S, Tanabe G, Baba M, Kuroshima K, Aikou T. The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer 2000, 89(6):1214-1219.
28. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J 1999, 13(8):773-780.
29. Session DR, Lee GS, Choi J, Wolgemuth DJ. Expression of cyclin E in gynecologic malignancies. Gynecol Oncol 1999, 72(1):32-37.
30. Demetrick DJ, Zhang H, Beach DH. Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). Cytogenet Cell Genet 1996, 73(1-2):104-107.
31. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999, 15:435-467.
32. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999, 97(4):431-434.
33. Imaki H, Nakayama K, Delehouzee S, Handa H, Kitagawa M, Kamura T, Nakayama KI. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. Cancer Res 2003, 63(15):4607-4613.
34. Sicari BM, Troxell R, Salim F, Tanwir M, Takane KK, Fiaschi-Taesch N. c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein. Endocrinology 2012, 153(2):861-872.
35. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 2001, 98(9):5043-5048.
36. Fotovati A, Abu-Ali S, Nakayama K, Nakayama KI. Impaired ovarian development and reduced fertility in female mice deficient in Skp2. J Anat 2011, 218(6):668-677.
37. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, Canzonieri V, D'Andrea S, Zucchetto A, Friedl P, Colombatti A, Baldassarre G. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 2008, 19(5):2003-2013.
38. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P, Breuhahn K. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 2009, 69(6):2234-2243.
39. Koutsami MK, Tsantoulis PK, Kouloukoussa M, Apostolopoulou K, Pateras IS, Spartinou Z, Drougou A, Evangelou K, Kittas C, Bartkova J, Bartek J, Gorgoulis VG. Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression. J Pathol 2006, 209(4):512-521.
40. Deb-Basu D, Karlsson A, Li Q, Dang CV, Felsher DW. MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2. Cell Cycle 2006, 5(12):1348-1355.
41. Nelsen CJ, Hansen LK, Rickheim DG, Chen C, Stanley MW, Krek W, Albrecht JH. Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2. Oncogene 2001, 20(15):1825-1831.
42. Honnappa S, Jahnke W, Seelig J, Steinmetz MO. Control of intrinsically disordered stathmin by multisite phosphorylation. J Biol Chem 2006, 281(23):16078-16083.
43. Steinmetz MO. Structure and thermodynamics of the tubulin-stathmin interaction. J Struct Biol 2007, 158(2):137-147.
44. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005, 7(1):51-63.